Merck, Daiichi post late-stage trial win for novel lung cancer therapy

koto_feja Merck ( NYSE: MRK ) and Daiichi Sankyo ( OTCPK:DSNKY ) announced Tuesday that their jointly developed lung cancer drug patritumab deruxtecan, which belongs to a new class of targeted cancer drugs called antibody-drug conjugates (ADC), met the primary endpoint in a Phase 3 trial.